Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicentre, Double-blind, Randomised, Placebo Controlled, Dose Escalation and Dose Finding Study to Evaluate the Efficacy and Safety of Dysport in Vulvodynia Patients

NCT03598777 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT03598777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03598777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicentre, Double-blind, Randomised, Placebo Controlled, Dose Escalation and Dose Finding Study to Evaluate the Efficacy and Safety of Dysport in Vulvodynia Patients
Lead sponsor
Ipsen
Phase
Phase 2
Overall status
Terminated
Start date
June 11, 2018
Completion date
January 21, 2021
Enrollment
60 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

vulvodynia